Highest-materiality recent filing
Oruka amended IL-23 license with Paragon to expand field to include inflammatory bowel disease (IBD).
Oruka Therapeutics closes 9.66M-share offering at $72.50; prelim cash $496M
Oruka completed underwritten public offering of 9,660,000 shares of common stock at $72.50 per share, raising gross proceeds of approximately $700 million.
Oruka Phase 2a EVERLAST-A meets primary endpoint: 63.5% PASI 100 at Week 16 in psoriasis
ORKA-001 achieved 63.5% (40/63) PASI 100 at Week 16 vs 4.8% placebo (p<0.0001), exceeding primary endpoint.
Oruka raises $180M; ORKA-001 Phase 1 shows ~100-day half-life, supports annual dosing
Private placement gross proceeds ~$180M; issued 10.9M shares at $15.00 and pre-funded warrants for 1.07M shares.
Oruka Therapeutics licenses IL-17A/F antibodies from Paragon; up to $22M in milestones
Exclusive worldwide license to develop and commercialize Paragon's anti-IL-17A/F antibodies.
Oruka Therapeutics enters exclusive IL-23 license with Paragon; up to $22M milestones
Oruka grants exclusive worldwide license for anti-IL-23 antibodies (ORKA-001) from Paragon, excluding inflammatory bowel disease.
Oruka raises $200M via PIPE; accelerates ORKA-001/002 clinical timelines
Gross proceeds of ~$200M from sale of common stock, preferred stock, and pre-funded warrants at $23.00 per common share.
ARCA completes reverse merger with Oruka; combined entity renamed Oruka Therapeutics (ORKA)
Merger closed: ARCA (shell) merges with private Oruka; Oruka shareholders own ~97.6% of combined company.
Shareholders approved all 9 proposals at Aug 22 special meeting, including merger, share increase to 545M, and reverse split.
ARCA biopharma declares special dividend of $1.59/share in connection with proposed Oruka merger
Special dividend estimated at $1.59 per share, payable to stockholders of record as of August 26, 2024.
ARCA biopharma Q2 net loss widens to $2.7M, cash $33.3M; merger with Oruka ongoing
Net loss $2.7M ($0.18/sh) vs $1.5M ($0.10) in Q2 2023, driven by $1.3M increase in G&A expenses.
ARCA biopharma Q1 net loss $2.0M, cash $35.9M; Oruka merger and CEO change detailed
Net loss for Q1 2024 was $2.0M ($0.14 per share) vs $1.3M ($0.09) in Q1 2023.
ARCA biopharma boosts CEO and CFO retention bonuses to $200K each
Board approved 33.33% increase in retention bonuses for Thomas A. Keuer and C. Jeffrey Dekker to $200,000 each.
CEO Michael Bristow departs ARCA biopharma; COO Thomas Keuer named President
Dr. Bristow's employment and board membership ended April 3, 2024 by mutual agreement, not due to any disagreement.
ARCA biopharma to merge with Oruka; Oruka holders to own ~97.6% of combined company
Oruka stockholders to own ~97.62% of the combined company; ARCA stockholders ~2.38%.
the Board appointed Thomas A. Keuer, the Company’s Chief Operating Officer, to serve as ARCA’s President and principal executive officer.
Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors (the “Board”) of ARCA have mutually agreed to conclude Dr. Bristow’s employment and service as a director, effective April 3, 2024.
On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “ Board ”) of ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), effective immediately.
On February 2, 2024, Raymond L. Woosley, M.D., Ph.D. and Dan Mitchell each resigned from the board of directors (the “ Board ”) of ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), effective immediately.
Max materiality 0.90 · Median 0.55 · Most common event other_material